Outcome of Board Meeting held on 10.11.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts less than Nifty Microcap 250 and 9.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astonea Labs' board approved unaudited H1 FY26 (ended 30 Sept 2025) results with an unmodified auditor opinion. Revenue from operations jumped to ₹6,629.14 lakhs from ₹4,727.04 lakhs in H1 FY25, a ~40% year-on-year rise. However, profit after tax fell sharply to ₹141.75 lakhs from ₹213.43 lakhs (~34% drop) as expenses grew faster than revenue, with cost of materials almost doubling. EPS slipped to ₹1.48 from ₹2.77. The board also authorised a revised distribution agreement with related party Astonea One Pvt Ltd, and appointed three new Non-Executive Non-Independent Directors (Mr. Arun Kumar Tripathi, Mr. Pardeep Dalal, Mr. Vikrant).
Positive revenue momentum is being offset by significant margin compression and weak cash generation — operating cash flow swung to a negative ₹2,977.09 lakhs versus positive ₹924.97 lakhs last year, largely due to ballooning trade receivables. Shareholders should watch whether receivables are collected and whether margins recover in H2, even as the balance sheet looks stronger post the June 2025 IPO.